SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
OSI Pharmaceuticals (OSIP) - formerly Oncogene
An SI Board Since December 1997
Posts SubjectMarks Bans Symbol
447 40 0 OSIP
Emcee:  James Reynolds Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
347<i>smith barney gives no respect to macugen they dont even mention that drDewDiligence_on_SI-1/18/2006
346smith barney gives no respect to macugen they dont even mention that drug as a csammaster-1/18/2006
345Smith Barney report on Lucentis: investorshub.comDewDiligence_on_SI-1/18/2006
344<i>do you think being a selective vegf inhibitor will not give [Macugen] aDewDiligence_on_SI-1/18/2006
343do you think being a selective vegf inhibitor will not give it a better side effsammaster-1/16/2006
342EYET pulled a fast one on them, IMHO. DME will not favor Macugen even if MacugeDewDiligence_on_SI-1/15/2006
341why did they purchase this drug last year if lucentis was going to come out so ssammaster-1/15/2006
340Addendum re Lucentis safety: investorshub.comDewDiligence_on_SI-1/14/2006
339One-year Lucentis data from ANCHOR study are superb: investorshub.comDewDiligence_on_SI-1/14/2006
338Sustained-release Macugen: investorshub.comDewDiligence_on_SI-1/11/2006
337I don't see anything about Phenomix, a private company founded a few years atuck-12/30/2005
336Not sure what today's bounce is about. Lucentis NDA today filed would seem tuck-12/30/2005
335>>MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 22, 2005--OSI Pharmaceuticals, Inctuck-12/22/2005
334[A therapeutic aptamer inhibits angiogenesis by specifically targeting the hepartuck-12/19/2005
333Updated scrip data again courtesy of ricardouno from YMB: finance.messages.yahotuck-12/19/2005
332Well, that could have been worse, particularly with the pretty low interest ratetuck-12/16/2005
331OSI Pharmaceuticals, Inc. Prices $100 Million 2.00% Convertible Senior SubordinaDoc Bones-12/16/2005
330New 8-K: >>ITEM 1.01 Entry into a Material Definitive Agreement On tuck-12/15/2005
329OSI issues $100 million in converts and will use up to 25% to buy back stock andtuck-12/15/2005
328>>MELVILLE, N.Y.--(BUSINESS WIRE)--Dec. 14, 2005--OSI Pharmaceuticals, Inctuck-12/14/2005
327Re: PSN9301, the DPIV inhibitor's results in PIIa for diabetes: Lehman weigtuck-12/9/2005
326<<What will be the incentive for docs to fool around with an unapproved anMiljenko Zuanic-12/8/2005
325<i>Wasn't you sceptical about Avastin [in AMD] few weeks back?</i&gDewDiligence_on_SI-12/8/2005
324<<1. Visudyne sales in the U.S. are being hurt by off-label use of AvastinMiljenko Zuanic-12/8/2005
323[Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolituck-12/8/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News